Latest Market Access News

St George Mining Limited (ASX: SGQ) has announced exceptional diamond drilling results from its Araxá Rare Earths and Niobium Project in Brazil, including the thickest intercept to date of 178.7m at 4.34% TREO and 0.75% Nb2O5 from surface. These results reinforce Araxá's status as a world-class undeveloped resource with potential for dual revenue streams from rare earths and niobium.

Nexsen Limited (ASX:NXN) has completed its Stage 1 ISO 13485 audit, confirming its Quality Management System (QMS) supports clinical validation and regulatory submissions for its diagnostic products, including StrepSure®. The company is progressing toward full certification and alignment with MDSAP requirements to facilitate global market access.

Duratec Limited is set to acquire Newcastle-based Pacific Welding Australia for up to $12 million, boosting its Energy and Mining sector footprint in NSW. The deal enhances Duratec’s self-perform capabilities and access to key Hunter Region clients.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

Prospect Resources has confirmed a continuous near-surface copper sulphide system over more than 1km at its West Mwombezhi prospect in Zambia, with a maiden resource estimate due in Q2 2026.

Galilee Energy has appointed a US Advisory Board to drive its Gulf Coast oil and gas expansion, targeting low-risk brownfield assets. The company’s maiden Zydeco-1 well in Louisiana is set to spud in Q2 2026, marking a key milestone in its US growth strategy.

Group 6 Metals has extended its offtake agreement with global trader Traxys, locking in a multi-year supply of tungsten concentrate valued at US$1.75 billion. This deal strengthens G6M’s market access amid growing demand for critical minerals.

Sprintex has cleared a key hurdle in a UK water utility procurement process, positioning itself for participation in a £104 billion infrastructure upgrade cycle focused on energy-efficient wastewater treatment.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

ARC Funds Limited’s trading suspension has been lifted following key announcements about new board appointments, signaling a fresh chapter for the investment manager.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.